Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
12.74
+0.16 (1.31%)
At close: Apr 28, 2026, 4:00 PM EDT
12.89
+0.16 (1.22%)
After-hours: Apr 28, 2026, 6:39 PM EDT
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Amneal Pharmaceuticals stock have an average target of 15.6, with a low estimate of 13 and a high estimate of 19. The average target predicts an increase of 22.50% from the current stock price of 12.74.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 2 |
| Buy | 3 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Initiates $19 | Strong Buy | Initiates | $19 | +49.20% | Apr 17, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $15 → $17 | Strong Buy | Maintains | $15 → $17 | +33.49% | Mar 2, 2026 |
| Barclays | Barclays | Buy Initiates $15 | Buy | Initiates | $15 | +17.79% | Dec 9, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $11 → $13 | Buy | Reiterates | $11 → $13 | +2.08% | Oct 31, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $12 → $14 | Buy | Maintains | $12 → $14 | +9.93% | Sep 16, 2025 |
Financial Forecast
Revenue This Year
3.15B
from 3.02B
Increased by 4.48%
Revenue Next Year
3.38B
from 3.15B
Increased by 7.13%
EPS This Year
1.01
from 0.22
Increased by 359.00%
EPS Next Year
1.20
from 1.01
Increased by 18.79%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.3B | 3.5B | |
| Avg | 3.2B | 3.4B | |
| Low | 3.0B | 3.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 8.1% | 11.4% | |
| Avg | 4.5% | 7.1% | |
| Low | -0.4% | 1.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.05 | 1.28 | |
| Avg | 1.01 | 1.20 | |
| Low | 0.96 | 1.09 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 377.3% | 26.9% | |
| Avg | 359.0% | 18.8% | |
| Low | 336.5% | 7.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.